A randomized, double‐blind, placebo‐controlled, multiple ascending dose study to evaluate the efficacy, pharmacokinetics, and safety of ABBV‐916 in adults with early Alzheimer’s disease
Preliminary data suggest that the safety and PK profile of ABBV-916 is comparable to currently approved anti-amyloid immunotherapies for the treatment of AD. Brain amyloid reduction was observed at doses of 300 mg or higher.
Authors
- D. Wang
- Hao Xiong (ORCID: https://orcid.org/0000-0001-6222-426X)
- Hana Florian
- Anthony W. Bannon
- Ole Graff
- Joey Boiser
- Edwin Stage
- Shau Yu Lynch
- Yamin Wang
- Sagar Bachhav
Institutions
- AbbVie (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_102775
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00